CR20210084A - Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) - Google Patents
Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)Info
- Publication number
- CR20210084A CR20210084A CR20210084A CR20210084A CR20210084A CR 20210084 A CR20210084 A CR 20210084A CR 20210084 A CR20210084 A CR 20210084A CR 20210084 A CR20210084 A CR 20210084A CR 20210084 A CR20210084 A CR 20210084A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- chimeric receptors
- antigen binding
- immune cells
- binding molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
<p>Las moléculas de unión al antígeno, los receptores quiméricos y las células inmunes manipuladas para CLL–1 se describen de acuerdo con la invención. La invención se refiere además a vectores, composiciones y métodos de tratamiento y/o detección utilizando las moléculas de unión al antígeno de CLL–1 y las células inmunes manipuladas</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317068P | 2016-04-01 | 2016-04-01 | |
PCT/US2017/025573 WO2017173384A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric receptors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210084A true CR20210084A (es) | 2021-03-26 |
Family
ID=59960746
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180480A CR20180480A (es) | 2016-04-01 | 2017-03-31 | Receptores quiméricos y métodos de uso de los mismos |
CR20210084A CR20210084A (es) | 2016-04-01 | 2017-03-31 | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180480A CR20180480A (es) | 2016-04-01 | 2017-03-31 | Receptores quiméricos y métodos de uso de los mismos |
Country Status (32)
Country | Link |
---|---|
US (3) | US10597456B2 (es) |
EP (2) | EP4180449A1 (es) |
JP (3) | JP2019513370A (es) |
KR (5) | KR20230165383A (es) |
CN (2) | CN113150170A (es) |
AR (1) | AR108066A1 (es) |
AU (3) | AU2017240788B2 (es) |
BR (1) | BR112018070260A2 (es) |
CA (2) | CA3177398A1 (es) |
CL (5) | CL2018002797A1 (es) |
CO (1) | CO2018010547A2 (es) |
CR (2) | CR20180480A (es) |
DK (1) | DK3436030T3 (es) |
EA (1) | EA201891992A1 (es) |
ES (1) | ES2930058T3 (es) |
HR (1) | HRP20221348T1 (es) |
HU (1) | HUE060645T2 (es) |
IL (1) | IL262041A (es) |
LT (1) | LT3436030T (es) |
MA (1) | MA43603A1 (es) |
MX (2) | MX2018012019A (es) |
MY (1) | MY197669A (es) |
PE (3) | PE20200400A1 (es) |
PH (1) | PH12018502113A1 (es) |
PL (1) | PL3436030T3 (es) |
PT (1) | PT3436030T (es) |
RS (1) | RS63735B1 (es) |
SG (2) | SG11201808595WA (es) |
SI (1) | SI3436030T1 (es) |
TW (4) | TWI792123B (es) |
UA (1) | UA123276C2 (es) |
WO (1) | WO2017173384A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
MA44498A (fr) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |
CR20180495A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Deribados de indol sustituidos como inhibidores de replicación viral del dengue |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
PE20190120A1 (es) | 2016-04-01 | 2019-01-17 | Kite Pharma Inc | Moleculas de union a bcma y metodos de uso de las mismas |
WO2017167952A1 (en) | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
JP2019513370A (ja) | 2016-04-01 | 2019-05-30 | カイト ファーマ インコーポレイテッドKite Pha | キメラ受容体及びその使用方法 |
IL303785A (en) * | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
BR112019024195A2 (pt) | 2017-05-22 | 2020-06-23 | Janssen Pharmaceuticals, Inc. | Composto e composição farmacêutica de derivados de indolina substituídos como inibidores da replicação viral da dengue |
EP3630724B1 (en) | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
EP3710471A1 (en) * | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
JP2022505921A (ja) * | 2018-10-26 | 2022-01-14 | カファ セラピューティクス リミテッド | Cll1を標的とする抗体およびその応用 |
BR112021016984A2 (pt) | 2019-03-01 | 2021-11-30 | Allogene Therapeutics Inc | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação |
EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | IMPROVEMENT OF POLYPEPTIDES AND CHIMERA ANTIGEN RECEPTORS ACROSS HINGE DOMAINS |
CN114729383A (zh) | 2019-07-02 | 2022-07-08 | 弗莱德哈钦森癌症研究中心 | 重组ad35载体及相关基因疗法改进 |
CA3154389A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd371 and uses thereof |
CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
CN113416713A (zh) * | 2021-05-11 | 2021-09-21 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种重组腺病毒的构建及其应用 |
WO2023147331A1 (en) | 2022-01-26 | 2023-08-03 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targetted antigen |
WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
JP4917035B2 (ja) | 2004-09-03 | 2012-04-18 | ゼネラル・モーターズ・コーポレーション | 燃料電池スタック内の繰返しおよび非繰返しユニットの位置合せ方法 |
WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
WO2009051974A1 (en) * | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
AU2009317161B2 (en) | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
PL2406284T3 (pl) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Przeciwciała anty-bcma |
AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
DE112010004469T5 (de) | 2009-11-17 | 2012-09-06 | Basf Plant Science Company Gmbh | Pflanzen mit erhöhtem Ertrag |
EP2566887A1 (en) | 2010-05-05 | 2013-03-13 | Addex Pharma SA | Chimeric receptors and methods for identifying agents exhibiting an activity on type 1 single pass transmembrane receptors |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
SG10201510092QA (en) | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
MX2013008376A (es) | 2011-01-18 | 2013-08-12 | Univ Pennsylvania | Composiciones y metodos para el tratamiento de cancer. |
WO2012103279A2 (en) | 2011-01-26 | 2012-08-02 | Ariad Pharmaceuticals, Incorporated | Methods and compositions for the synthesis of multimerizing agents |
BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
RS64791B1 (sr) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - vezujući proteini |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
ES2829499T3 (es) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Método para la selección de anticuerpos contra BCMA |
NZ750426A (en) | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
HUE047487T2 (hu) | 2013-02-15 | 2020-04-28 | Univ California | Kiméra antigénreceptor és eljárások alkalmazására |
CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
US9629877B2 (en) | 2013-05-14 | 2017-04-25 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
CA2930587A1 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
CN114395530A (zh) | 2014-02-04 | 2022-04-26 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
AU2015218396A1 (en) | 2014-02-14 | 2016-08-11 | Bellicum Pharmaceuticals, Inc. | Methods for activating T cells using an inducible chimeric polypeptide |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
US10316101B2 (en) | 2014-04-14 | 2019-06-11 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
SG11201700418VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
EP3193592A1 (en) | 2014-09-19 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
BR122024000360A2 (pt) | 2014-09-19 | 2024-02-27 | City Of Hope | Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso |
MX2017007250A (es) | 2014-12-05 | 2018-02-16 | Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1. | |
EP3640262A1 (en) | 2014-12-12 | 2020-04-22 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy |
TWI703157B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Cd3特異性抗體、治療性雙特異性抗體及其用途 |
SG10201912666PA (en) | 2015-04-13 | 2020-02-27 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
JP2019513370A (ja) | 2016-04-01 | 2019-05-30 | カイト ファーマ インコーポレイテッドKite Pha | キメラ受容体及びその使用方法 |
SG10201911963VA (en) | 2016-04-01 | 2020-02-27 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
PE20190120A1 (es) | 2016-04-01 | 2019-01-17 | Kite Pharma Inc | Moleculas de union a bcma y metodos de uso de las mismas |
-
2017
- 2017-03-31 JP JP2018551953A patent/JP2019513370A/ja active Pending
- 2017-03-31 MA MA43603A patent/MA43603A1/fr unknown
- 2017-03-31 DK DK17776859.5T patent/DK3436030T3/da active
- 2017-03-31 PT PT177768595T patent/PT3436030T/pt unknown
- 2017-03-31 PE PE2019002307A patent/PE20200400A1/es unknown
- 2017-03-31 CN CN202110248927.7A patent/CN113150170A/zh active Pending
- 2017-03-31 CN CN201780022074.7A patent/CN109641008B/zh active Active
- 2017-03-31 SI SI201731265T patent/SI3436030T1/sl unknown
- 2017-03-31 US US15/476,699 patent/US10597456B2/en active Active
- 2017-03-31 CR CR20180480A patent/CR20180480A/es unknown
- 2017-03-31 PE PE2020001605A patent/PE20211418A1/es unknown
- 2017-03-31 KR KR1020237040899A patent/KR20230165383A/ko not_active Application Discontinuation
- 2017-03-31 BR BR112018070260A patent/BR112018070260A2/pt active Search and Examination
- 2017-03-31 PL PL17776859.5T patent/PL3436030T3/pl unknown
- 2017-03-31 RS RS20221024A patent/RS63735B1/sr unknown
- 2017-03-31 UA UAA201809953A patent/UA123276C2/uk unknown
- 2017-03-31 KR KR1020227039755A patent/KR102608405B1/ko active IP Right Grant
- 2017-03-31 MY MYPI2018703599A patent/MY197669A/en unknown
- 2017-03-31 HU HUE17776859A patent/HUE060645T2/hu unknown
- 2017-03-31 WO PCT/US2017/025573 patent/WO2017173384A1/en active Application Filing
- 2017-03-31 MX MX2018012019A patent/MX2018012019A/es unknown
- 2017-03-31 AU AU2017240788A patent/AU2017240788B2/en active Active
- 2017-03-31 CA CA3177398A patent/CA3177398A1/en active Pending
- 2017-03-31 HR HRP20221348TT patent/HRP20221348T1/hr unknown
- 2017-03-31 EP EP22191077.1A patent/EP4180449A1/en active Pending
- 2017-03-31 SG SG11201808595WA patent/SG11201808595WA/en unknown
- 2017-03-31 KR KR1020207015941A patent/KR20200068750A/ko active Application Filing
- 2017-03-31 KR KR1020217021089A patent/KR20210089262A/ko active Application Filing
- 2017-03-31 EP EP17776859.5A patent/EP3436030B1/en active Active
- 2017-03-31 ES ES17776859T patent/ES2930058T3/es active Active
- 2017-03-31 KR KR1020187031572A patent/KR102120815B1/ko active IP Right Grant
- 2017-03-31 LT LTEPPCT/US2017/025573T patent/LT3436030T/lt unknown
- 2017-03-31 EA EA201891992A patent/EA201891992A1/ru unknown
- 2017-03-31 AR ARP170100821A patent/AR108066A1/es unknown
- 2017-03-31 SG SG10201912519VA patent/SG10201912519VA/en unknown
- 2017-03-31 CA CA3019650A patent/CA3019650C/en active Active
- 2017-03-31 CR CR20210084A patent/CR20210084A/es unknown
- 2017-03-31 PE PE2018001934A patent/PE20190356A1/es unknown
- 2017-04-05 TW TW109145084A patent/TWI792123B/zh active
- 2017-04-05 TW TW112101087A patent/TW202319537A/zh unknown
- 2017-04-05 TW TW109107507A patent/TWI714470B/zh active
- 2017-04-05 TW TW106111224A patent/TW201803896A/zh unknown
-
2018
- 2018-10-01 CO CONC2018/0010547A patent/CO2018010547A2/es unknown
- 2018-10-01 MX MX2023002556A patent/MX2023002556A/es unknown
- 2018-10-01 CL CL2018002797A patent/CL2018002797A1/es unknown
- 2018-10-01 PH PH12018502113A patent/PH12018502113A1/en unknown
- 2018-10-02 IL IL262041A patent/IL262041A/en unknown
-
2019
- 2019-08-14 CL CL2019002310A patent/CL2019002310A1/es unknown
- 2019-10-21 US US16/658,480 patent/US20200115457A1/en not_active Abandoned
-
2020
- 2020-06-15 AU AU2020203990A patent/AU2020203990A1/en not_active Abandoned
- 2020-09-11 JP JP2020152515A patent/JP7134204B2/ja active Active
- 2020-10-15 CL CL2020002677A patent/CL2020002677A1/es unknown
-
2021
- 2021-06-30 CL CL2021001750A patent/CL2021001750A1/es unknown
-
2022
- 2022-07-08 CL CL2022001873A patent/CL2022001873A1/es unknown
- 2022-08-30 JP JP2022136417A patent/JP7451627B2/ja active Active
-
2023
- 2023-03-03 US US18/178,086 patent/US20230331855A1/en active Pending
- 2023-07-24 AU AU2023208077A patent/AU2023208077A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
PH12018502118A1 (en) | Chimeric receptors to flt3 and methods of use thereof | |
PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
WO2015109124A3 (en) | Immunomodulatory agents | |
MX2016016881A (es) | Anticuerpos que se unen a axl. | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
PH12021550120A1 (en) | Chimeric receptors to steap1 and methods of use thereof | |
MX2016012479A (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
MX2018009218A (es) | Anticuerpos de cgrp y sus usos. |